ArticleEuropean urology2021
Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
Article in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 81 citations in OpenAlex.
- Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.JAMA network open · 2024Trial
- Integrating Artificial Intelligence into Prostate MR Imaging: Technical Foundations, Clinical Applications, and Workflow Implications.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Review
- Article
- Article
- European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance.Insights into imaging · 2026Article
- Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.BJU international · 2026Article
- Prospective validation of an AI software for detecting clinically significant prostate cancer on biparametric MRI.Insights into imaging · 2026Article
- Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant.Journal of the National Cancer Institute · 2026Article
- Transgluteal MRI-targeted biopsy versus transrectal systemic biopsy in prostate cancer diagnosis.International urology and nephrology · 2025Article
- Overview of Performance Indicators of Prostate Cancer Screening Trials.European urology open science · 2025Review
- Long-term follow-up after initial negative prostate biopsy-comparison of conventional transrectal ultrasound biopsy and mpMRI/transrectal ultrasound fusion guided biopsy.Translational andrology and urology · 2025Article
- Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.BJU international · 2025Article
- Optimizing clinical risk stratification of localized prostate cancer.Current opinion in urology · 2025Review
- Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller Tumors.European urology open science · 2025Article
- Impact of Prebiopsy Multiparametric Magnetic Resonance Imaging on Prostate Cancer Detection in Switzerland.European urology open science · 2025Article
- Mapping of prostate cancer microvascular patterns using super-resolution ultrasound imaging.European radiology experimental · 2025Article
- Reevaluating the Definition of Clinically Significant Prostate Cancer as Grade Groups 2 to 5: An Imperative for Improved Risk Stratification.The Journal of urology · 2025Article
- Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance.Clinical genitourinary cancer · 2024Article
- Article
- Early experience with targeted and combination biopsies in prostate cancer work-up in Denmark from 2012 to 2016.World journal of urology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundIt has been suggested that targeting prostate lesions identified on magnetic resonance imaging (MRI) will improve the sensitivity of prostate biopsy for high-grade disease. The clinical significance of high-grade tumors found on MRI but missed on systematic biopsy is open to question.
objectiveTo determine the risk of mortality for high-grade cancers identified by MRI targeting in men who had benign systematic biopsy findings. DESIGN, SETTING, AND
participantsWe used data from 999 men with negative systematic biopsy and concurrent MRI-targeted biopsy in the National Cancer Institute MRI study. The comparison group consisted of 3056 men followed for 11 yr after negative sextant biopsy in the European Randomized Trial of Screening for Prostate Cancer (ERSPC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We calculated the number of patients needed to be diagnosed (NND) and treated (NNT) following targeted biopsy in order to prevent one prostate cancer death at 11 yr. We used a simple modeling approach that involved several assumptions, such as the proportion of the deaths in ERSPC preventable by earlier detection with MRI-guided biopsy. We then varied these assumptions to assess the effects on the results. RESULTS AND LIMITATIONS: NND and NNT were 89 and 57 for the scenario involving assumptions favorable to MRI, and 169 and 127 for a more neutral set of assumptions, respectively. Results were only more encouraging for MRI targeting under unlikely scenarios, such as 100% sensitivity for MRI and a cure rate of 100% for treatment.
conclusionsAlthough MRI may be of benefit overall, considering the decrease in overdiagnosis among men with negative MRI findings, targeting biopsy needles to MRI-detected lesions results in a large number of men diagnosed and treated per death prevented. Consideration should be given to changing guidelines on grading of MRI cores and those regarding treatment of MRI-detected high-grade prostate cancer. PATIENT SUMMARY: We carried out a modeling study to assess how magnetic resonance imaging (MRI) scan results used to target prostate cancer lesions during biopsy can affect outcomes. The model results show that if MRI-visible tumors are targeted during prostate biopsy, a large number of men need to be diagnosed and treated for prostate cancer in order to avoid just one prostate cancer death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.